Q2 2024 InspireMD Inc Earnings Call Transcript
Key Points
- InspireMD Inc (NSPR) presented one-year outcomes data for the C-GUARDIANS clinical trial, showing a major events rate of just 1.95%, the lowest of any carotid pivotal trial to date.
- The company is on track to submit a premarket approval application to the FDA this quarter, aiming for a US commercial launch of CGuard Prime in the first half of 2025.
- InspireMD Inc (NSPR) raised $17.9 million in gross proceeds from the exercise of Series H warrants, supporting its financial position.
- The company reported a 5.4% increase in total CGuard revenue for the quarter, with significant growth in production to meet anticipated market demand.
- InspireMD Inc (NSPR) is actively preparing for US market entry, including establishing a US headquarters in Southeast Florida and building a world-class commercial team.
- Gross profit decreased by 32.6% to $331,000, primarily due to increased material and labor costs, and additional expenses related to scaling up for the US launch.
- Operating expenses increased by 48% to $8,591,000, driven by higher compensation and development expenses, including non-cash share-based compensation.
- Net loss for the second quarter of 2024 was $7,909,000, compared to a net loss of $5,077,000 in the same period of 2023.
- The company faces challenges in navigating value analysis committees and reimbursement processes for the US market entry.
- Despite positive trial results, InspireMD Inc (NSPR) still needs to secure FDA approval and successfully execute its US commercial launch strategy.
Good morning, and welcome to the InspireMD second quarter 2024 earnings call. Currently, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. (Operator Instructions)
Please note, this conference is being recorded.
I will now turn the conference over to Chuck Padala with Life Advisors. Thank you. You may begin
Thank you, operator, and good morning, everyone. Thank you for joining us for the InspireMD second quarter financial results and corporate update conference call.
Joining us today from InspireMD are Marvin Slosman, Chief Executive Officer; and Craig Shore, Chief Financial Officer. During this call, management will be making forward-looking statements, not historical facts, which are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. These forward-looking statements involve risks and uncertainties that may cause actual results
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
